Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials

European Journal of Cancer · Published 2026-07-23 · DOI 10.1016/j.ejca.2026.116960

Authors (25)

Paul Matte, Nael Alshatti, Matthieu Roulleaux-Dugage, Jean-Eudes Fahrner, Capucine Baldini, Stéphane Champiat, Damien Vasseur, Kaïssa Ouali, Anas Gazzah, Rastislav Bahleda, Arnaud Bayle, Sophie Postel-Vinay, Madona Sakkal, Jean-Marie Michot, Antoine Hollebecque, Nathalie Chaput, Yohann Loriot, Eric Deutsch, Antoine Italiano, Pauline Vaflard, Celia Dupain, Christophe Le Tourneau, Christophe Massard, Aurélien Marabelle, François-Xavier Danlos

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Matte, P., Alshatti, N., Roulleaux-Dugage, M., et al. (2026). Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116960

Related articles

• Temporal linguistic shifts in oncology randomized controlled trials following large language model availability: A corpus analysis of 21,392 publications · European Journal of Cancer · 2026 · Same journal
• Risk of recurrence of stage I to III melanoma in Norway, 2008–2022 · European Journal of Cancer · 2026 · Same journal
• The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients – Results from the UK MRC OE02 trial · European Journal of Cancer · 2026 · Same journal
• Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4) · European Journal of Cancer · 2026 · Same journal
• Letter-to-the-editor Re: “Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC” · European Journal of Cancer · 2026 · Same journal
• Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial · European Journal of Cancer · 2026 · Same journal
• Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy · European Journal of Cancer · 2026 · Same journal
• Tumor treating fields: Will the evidence gap ever be filled? · European Journal of Cancer · 2026 · Same journal
• Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience · European Journal of Cancer · 2026 · Same journal
• Management of critically ill cancer patients. Expert consensus statement of the “Intensive Care for Hematology and Oncology Patients” (iCHOP) Working Group of the German Society of Hematology and Oncology (DGHO), Austrian Society of Hematology and Oncology (OeGHO), German Society for Medical Intensive Care Medicine and Emergency Medicine (DGIIN), and Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN) · European Journal of Cancer · 2026 · Same journal